世卫新冠疫苗机制将加快全球供应 5月底前提供近2.4亿剂
《路透》报道,世卫新冠疫苗全球获取机制(COVAX)周二(2日)表示将加快全球疫苗供应,5月底前将向142个国家提供2.37亿剂阿斯利康(AZN.US)疫苗。
COVAX发表声明指,疫苗配送将划分成两批不同时段,每个时段为期两个月,首批在2月至3月,第二批在4月至5月,由阿斯利康及印度血清研究所负责生产。声明提到,时间表取决於多个因素,包括国家监管要求、可用供应以及是否满足其他标准,例如经过验证的国家部署和疫苗接种计划。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.